

STEREOTACTIC BODY RADIATION THERAPY (SBRT)

This Model Policy¹ addresses coverage for stereotactic body radiation therapy (SBRT).

Description

SBRT is a radiation treatment modality that couples a high degree of anatomic targeting accuracy and reproducibility with very high doses of extremely precise, externally generated, ionizing radiation. The therapeutic intent of SBRT is to maximize cell-killing effect on the target(s) while minimizing radiation-related injury in adjacent normal tissues. SBRT is used to treat extra-cranial sites as opposed to stereotactic radiosurgery (SRS), which is used to treat intra-cranial. For a discussion of the codes relevant to SRS, refer to ASTRO's SRS Model Policy¹¹.

The adjective "stereotactic" describes a procedure during which a target lesion is localized relative to a known three-dimensional reference system that allows for a high degree of anatomic accuracy. Examples of devices used in SBRT for stereotactic guidance may include a body frame with external reference markers in which a patient is positioned securely, a system of implanted fiducial markers that can be visualized with low-energy (kV) X-rays and CT imaging-based systems used to confirm the location of a tumor immediately prior to treatment.

Treatment

SBRT Treatment Planning

Treatment planning for SBRT generally follows the same process and procedures as IMRT and three-dimensional conformal therapy plans. As with either treatment planning methods, SBRT planning determines the field size(s), gantry angles and other beam characteristics to achieve the desired radiation dose distribution. SBRT plans are highly customized to the target volume(s) and may be geometrically more accurate than conventionally fractionated external beam treatment plans.

Imaging

Three-dimensional image acquisition of the target region by simulation is an essential prerequisite to SBRT treatment planning. In general, a CT scan of the target region is performed and serves as the baseline image set used for dose calculations and, for selected cases, for coregistration of MR or PET images sets in order to better define the target and surrounding anatomy. If respiratory or other normal organ motion is expected to produce significant movement of the target region during radiation therapy delivery, the radiation oncologist may additionally elect to order multiphase treatment planning image sets to account for motion when rendering target volumes. Some SBRT treatment systems such as automated robotic delivery may not require multiphase imaging but is still able to deliver breathing-corrected treatment.

¹ ASTRO model policies were developed as a means to efficiently communicate what ASTRO believes to be correct coverage policies for radiation oncology services. The ASTRO model policies do not serve as clinical guidelines and they are subject to periodic review and revision without notice. The ASTRO Model Policies may be reproduced and distributed, without modification, for noncommercial purposes.



a. Contouring

Defining the target and avoidance structures is a multi-step process:

- i. The radiation oncologist reviews the three-dimensional images and outlines the treatment target on each slice of the image set. The summation of these contours defines the Gross Tumor Volume (GTV). For multiple image sets, the physician may outline separate GTVs on each image set to account for the effect of normal organ motion upon target location and shape. Some patients may not have GTVs if they have had previous treatment with surgery or chemotherapy, in which case treatment planning will be based on CTVs as described below.
- ii. The radiation oncologist draws a margin around the GTV to generate a Clinical Target Volume (CTV), which encompasses the areas at risk for microscopic disease (i.e., not visible on imaging studies). Other CTVs may be created based on the estimated volume of residual disease. For multiple image sets, the physician may draw this margin around an aggregate volume containing all image set GTVs to generate an organ-motion CTV, or Internal Target Volume (ITV).
- iii. To account for potential daily patient setup variation and/or organ and patient motion, a final margin is then added to create a Planning Target Volume (PTV).
- iv. Nearby normal structures that could potentially be harmed by radiation (i.e., “organs at risk” or OARs) are also contoured.

b. Radiation dose prescribing

The radiation oncologist assigns specific dose requirements for the PTV, which typically includes a prescribed dose that must be given to at least 90 to 95 percent of the PTV. Additionally, PTV dose requirements routinely include dose constraints for the OARs (e.g., upper limit of mean dose, maximum allowable point dose and/or a critical volume of the OAR that must not receive a dose above a specified limit). A treatment plan that satisfies these requirements and constraints should maximize the potential for disease control and minimize the risk of radiation injury to normal tissue.

c. Dosimetric planning, calculations and dose verification

The medical physicist or a supervised dosimetrist calculates a multiple static beam and/or modulated arc treatment plan to deliver the prescribed radiation dose to the PTV and simultaneously satisfy the normal tissue dose constraints by delivering significantly lower doses to nearby organs. Dose-volume histograms are prepared for the PTV and OARs. Here, an arc is defined as a discrete complete or partial rotation of the linear accelerator gantry during which there is continuous motion of the multileaf collimator (MLC) to deliver an optimized radiation dose distribution within the patient. The calculated beams or arcs are then delivered either to a phantom or a dosimetry measuring device to confirm that the intended dose distribution for the patient is physically verifiable and that the beams or arcs are technically feasible.

Documentation of all aspects of the treatment planning process is essential.

SBRT Treatment Delivery

Treatment of extra-cranial sites requires accounting for internal organ motion as well as for patient motion. Thus, reliable immobilization or repositioning systems must often be combined with devices capable of decreasing organ motion or accounting for organ motion – e.g., use of respiratory gating or robotic target tracking for target sites in the chest or upper abdomen. Additionally, all SBRT is performed with at least one form of image guidance to confirm proper patient positioning and tumor localization prior to delivery of each fraction. The ASTRO/ACR Practice Guidelines for SBRT outline the responsibilities and training requirements for personnel involved in the administration of SBRT⁹.

SBRT may be delivered in one to five sessions (fractions). Each fraction requires an identical degree of precision, localization and image guidance. Since the goal of SBRT is to maximize the potency of the radiation therapy by completing an entire course of treatment within an extremely accelerated time frame, any course of radiation

treatment extending beyond five fractions is not considered SBRT and is not to be billed as such. SBRT is meant to represent a complete course of treatment and not be used as a boost following a conventionally fractionated course of treatment.

SBRT may be used as an alternative to surgery for treating various lesions and may be an effective and safer alternative than conventional radiation therapy for certain presentations of cancers and other non-cancer targets. Direct physician involvement, image guidance and immobilization are integral to stereotactic treatment for these diverse body sites. The medical physicist should perform a second check calculation before initiating the first treatment to ensure the monitor units used to deliver the planned treatment are correct. With a radiation oncologist, the medical physicist should ensure all of the treatment parameters are correct, including image guidance, respiratory motion compensation or any other complex positioning aids that may be employed to accurately treat the patient.

Documentation Requirements

The patient's record must support the medical necessity of treatment. Supporting clinical records should include not only the patient's medical history and physical examination findings but also the patient's current functional status, commonly described by an overall performance status score (e.g., Karnofsky Performance Status or Eastern Cooperative Oncology Group (ECOG) Performance Status score). A radiation oncologist must evaluate the clinical and technical aspects of the treatment and document this evaluation as well as the resulting management decision. Clinical record documentation of the technical aspects of treatment planning and delivery should include details of the prescribed dose to the target and relevant dose-limiting normal structures and the actual dose delivered and dates of treatment delivery. For Medicare claims of SBRT, the HCPCS/CPT® code(s) may be subject to Correct Coding Initiative (CCI) edits. This policy does not take precedence over CCI edits. Please refer to the CCI for correct coding guidelines and specific applicable code combinations prior to billing Medicare.

Indications and Limitations of Coverage and/or Medical Necessity

Indications for Coverage

SBRT is indicated for primary tumors and tumors metastatic to the lung, liver, kidney, adrenal gland or pancreas.

SBRT is also indicated for treatment of pelvic and head and neck tumors that have recurred after primary irradiation when each of the following criteria is met, and each is specifically documented in the medical record.

1. The patient's general medical condition (namely, the performance status) justifies aggressive, curative treatment to a primary, non-metastatic cancer, or
2. Metastatic disease requiring palliation cannot be treated by conventional methods due to proximity of adjacent prior irradiated volumes and other measures are not appropriate or safe for the particular patient, or
3. The patient's general medical condition (namely, the performance status) justifies aggressive local therapy to one or more deposits of metastatic cancer in an effort either to achieve total disease clearance in the setting of oligometastatic disease or to reduce the patient's overall burden of systemic disease for a specifically defined clinical benefit, and
4. The targeted tumor(s) can be completed encompassed with acceptable risk to nearby critical normal structures.

Multiple ICD diagnosis codes fit this description of covered indications and are listed in this coverage policy below.

Other Neoplasms

a. Prostate Cancer

Many clinical studies supporting the efficacy and safety of SBRT in the treatment of localized prostate cancer have been published. At least one study has shown excellent five-year biochemical control rates with very low rates of serious toxicity. Additionally, numerous studies have demonstrated the safety of SBRT for prostate cancer after a follow-up interval long enough (two to three years) to provide an opportunity to observe the incidence of late genitourinary or gastrointestinal toxicity.

While it is necessary to observe patients treated for prostate cancer for extended intervals to gauge the rate of long-term (e.g., beyond 10 years) biochemical control and overall survival, the interim results reported appear at least as good as other forms of radiation therapy administered to patients with equivalent risk levels followed for the same post-treatment duration.

It is ASTRO's opinion that data supporting the use of SBRT for prostate cancer have matured to a point where SBRT should be considered an appropriate alternative for select patients with low- to intermediate-risk disease.

b. Bone Metastases

SBRT has been demonstrated to achieve durable tumor control when treating lesions in vertebral bodies or the paraspinal region, where extra care must be taken to avoid excess irradiation of the spinal cord when tumor-ablative doses are administered. There is an important clinical distinction between the status of patients described above and a patient with widely metastatic disease for whom palliation is the major objective. In one setting, a patient with limited metastatic disease and good performance status is treated with the intention of eradicating all known active disease or greatly reducing the total disease burden in a manner that can extend progression-free survival. For such a patient, SBRT can be a reasonable therapeutic intervention. However, for uncomplicated, previously untreated bone metastases in a patient with widespread progressive disease in the spine or elsewhere and where the prognosis is unfavorable, it is generally appropriate to use a less technically complex form of palliative radiation therapy rather than SBRT.

c. Other Indications for SBRT

For patients with tumors of any type arising in or near previously irradiated regions, SBRT may be appropriate when a high level of precision and accuracy is needed to minimize the risk of injury to surrounding normal tissues. Also, in other cases where a high dose per fraction treatment is indicated SBRT may be appropriate. The medical necessity for SBRT should be documented in the patient's medical record.

ICD-9-CM and ICD-10-CM Codes That May Be Associated with Medical Necessity

Note: Diagnosis codes are based on the current ICD-9-CM codes that are effective at the time of Model Policy publication. Any updates to ICD-9-CM or ICD-10-CM codes will be reviewed by ASTRO, and coverage should not be presumed until the results of such review have been published.

The following ICD diagnosis codes support medical necessity under this Model Policy:

DIAGNOSIS	ICD-9 CODE(S)	ICD-10 CODE(S)
PRIMARY TUMORS		
Lung cancer	162.2 - 162.9	C34.00 – C34.92
Prostate cancer	185	C61
Pancreatic cancer	157.0-157.9	C25.0-C25.9
Renal cancer	189.0, 189.1	C64.1-C65.9
Liver or bile duct cancer	155.0, 155.1, 155.2	C22.0-C22.9
Adrenal gland cancer	194.0, 194.6	C74.00-C74.92 C75.5
METASTATIC TUMORS		
Lung metastasis	197.0	C78.00-C78.02
Liver metastasis	197.7	C78.7
Renal metastasis	198.0	C79.00-C79.02
Adrenal gland metastasis	198.7	C79.70-C79.72
Thoracic lymph nodes metastasis	196.1	C77.1
Bone metastasis	198.5	C79.51, C79.52
RECURRENT TUMORS AFTER PRIOR RT		
Abdominal and pelvic cancer	195.2, 195.3	C76.2, C76.3
Gynecologic cancer	179-184.9	C51.0-C58
Rectal and anal cancer	154.0-154.8	C19-C21.8
Head and neck cancer	140.0-146.8 147.0-149.9 160.0-161.9	C00.0-C10.8 C11.0-C14.8 C30.0-C32.9
Lymph node metastasis	196.0-196.9	C77.0-C77.9
Prior radiotherapy, any site	990*	T66.XXXA*

**ICD-9-CM 990 or ICD-10-CM T66.XXXA (Effects of Radiation, Unspecified) may only be used where prior radiation therapy to the site is the governing factor necessitating SBRT in lieu of other radiation therapy. An ICD diagnosis code for the anatomic diagnosis must also be used.*

Limitations of Coverage

SBRT is not considered medically necessary under any of the following circumstances:

1. Treatment is unlikely to result in clinical cancer control and/or functional improvement.
2. The tumor burden cannot be completely targeted with acceptable risk to nearby critical normal structures.
3. Patients with poor performance status (Karnofsky Performance Status less than 40 or ECOG Status of 3 or worse; see below for further scoring information regarding Karnofsky Performance Status and ECOG Status).

Karnofsky Performance Status Scale⁴

100	Normal; no complaints, no evidence of disease.
90	Able to carry on normal activity; minor signs or symptoms of disease.
80	Normal activity with effort; some signs or symptoms of disease.
70	Cares for self; unable to carry on normal activity or to do active work.
60	Requires occasional assistance but is able to care for most needs.
50	Requires considerable assistance and frequent medical care.
40	Disabled; requires special care and assistance.
30	Severely disabled; hospitalization is indicated although death not imminent.
20	Very sick; hospitalization necessary; active supportive treatment is necessary.
10	Moribund, fatal processes progressing rapidly.
0	Dead.

ECOG Performance Status Scale⁸

- Grade 0:** Fully active, able to carry on all pre-disease performance without restriction.
- Grade 1:** Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
- Grade 2:** Ambulatory and capable of all self-care but unable to carry out and work activities. Up and about more than 50 percent of waking hours.
- Grade 3:** Capable of only limited self-care, confined to bed or chair more than 50 percent of waking hours.
- Grade 4:** Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.
- Grade 5:** Dead.

Physicians' Current Procedural Terminology (CPT®)/HCPCS Section

Note: CPT is a trademark of the American Medical Association (AMA).

SBRT Treatment Planning

There are no specific codes for clinical treatment planning and simulation for SBRT. However, because of the complexity of SBRT and the need for three-dimensional conformal or IMRT dosimetric treatment planning, the following codes are usually appropriate for SBRT cases. Use of IMRT planning is based on the delivery system and medical necessity.

CPT® CODE	DESCRIPTION	SBRT-SPECIFIC GUIDELINES
77263	Therapeutic radiology treatment planning; complex	Given the complexity of clinical decision-making for SBRT, a complex clinical treatment planning code is justified.
+77293	Respiratory motion management simulation (List separately in addition to code for primary procedure).	May be reasonable to perform and report once per course of SBRT for cases in which target movement during respiration must be accounted for during treatment planning (e.g., tumors of the thorax and upper abdomen).
77295 OR 77301	3-dimensional radiotherapy plan, including dose-volume histograms Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications (Dose plan is optimized using inverse planning technique for modulated beam delivery [eg, binary, dynamic MLC] to create highly conformal dose distribution. Computer plan distribution must be verified for positional accuracy based on dosimetric verification of the intensity map with verification of treatment set-up and interpretation of verification methodology)	Report either treatment planning code only once per course of SBRT.
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation) (77470 assumes that the procedure is performed 1 or more times during the course of therapy, in addition to daily or weekly patient management) (For intraoperative radiation treatment delivery and management, see 77424, 77425, 77469)	Given additional time and effort required of SBRT, a special treatment procedure code may be justified with appropriate specific documentation.

Medical Radiation Physics, Dosimetry and Treatment Devices

There are no SBRT specific codes for medical radiation physics, dosimetry, treatment devices and special services. However, the following codes can be used as described below.

CPT® CODE	DESCRIPTION	SBRT-SPECIFIC GUIDELINES
77300	Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, only when prescribed by the treating physician	One unit for each arc in linear accelerator system. One unit for each shot in Cobalt-60. Maximum limit of 10 units.
77370	Special medical radiation physics consultation	May be reasonable and necessary if ordered by the radiation oncologist.
77334	Treatment devices, design and construction; complex (irregular blocks, special shields, compensators, wedges, molds or casts)	One unit for each unique combination of beam angle and collimator pattern or each unique arc; certain carrier limitations may apply. One unit for each helmet in Cobalt-60.
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction, per IMRT plan	If IMRT planning code 77301 is used for coding treatment planning then one CPT 77338 should be used to code for the devices.

SBRT Treatment Delivery

Historically, in the hospital outpatient environment, CMS has utilized G-codes to distinguish between robotic and non-robotic SBRT and SRS. The agency recently reviewed current radiation therapy equipment technology and found that most linac-based treatment platforms incorporate some type of robotic capability. CMS therefore concluded that it is no longer necessary to continue distinguishing robotic and non-robotic linear accelerators.

Beginning January 1, 2014, CPT® code 77373 can be reported in place of HCPCS codes G0251, G0339 and G0340. The chart below provides a crosswalk of CPT and corresponding HCPCS codes:

HCPCS CODE	DESCRIPTOR	CPT® CODE	DESCRIPTOR
G0251	Linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment	77373	SBRT delivery
G0339	Image-guided robotic linear accelerator-based stereotactic radiosurgery, course of therapy in one session, or first session of fractionated treatment		
G0340	Image-guided robotic linear accelerator-based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, second through fifth sessions, maximum five sessions per course of treatment		

CPT® CODE	DESCRIPTION	SBRT-SPECIFIC GUIDELINES
77373	<p>Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions</p> <p>(Do not report 77373 in conjunction with 77385, 77386, 77401, 77402, 77407, 77412)</p> <p>(For single fraction cranial lesion[s], see 77371, 77372)</p>	<p>Technical code for up to but no more than 5 fractions in the freestanding setting. This code includes all image guidance on the days of treatment delivery; therefore, do not report 77373 in conjunction with 77014 on the days of treatment delivery. This code will be paid only once per day of treatment regardless of the number of sessions or lesions.</p> <p>Note that this code should be used in place of 0082T, which has been deleted as of January 1, 2007.</p>

When reporting SBRT delivery, it is not appropriate to bill more than one treatment delivery code on the same date of service, even though stereotactic therapy may be delivered using either conformal or intensity modulated techniques (e.g., SBRT delivered using MLC-modulated beams should be reported using CPT code 77373 only and not using 77373 with 77385 or 77386). Likewise, only one SBRT delivery unit is to be reported even if multiple targets are treated using different setup and field arrangement parameters on the same day.



Radiation Treatment Management

CPT® Category I code 77435 (SBRT treatment management) should be used by the radiation oncologist to report treatment management during SBRT. This code may be reported once per SBRT course.

The physician work for 77435 can be summarized as follows: The radiation oncologist evaluates the patient prior to the procedure. Under the direct supervision of the radiation oncologist, the patient is set up on the treatment table and all the treatment parameters are verified. Image guidance and respiratory correlation, if required, may be achieved through a variety of methods, all of which are supervised, corrected and approved in real-time by the physician. The physician assesses and approves all of the ongoing images used for localization, tumor tracking and any gating application, as well as any complementary single (beam’s eye) view localization images for any of the fields or arcs used to deliver a dose. The radiation oncologist remains available throughout SBRT treatment to manage the execution of the treatment and make real-time adjustments in response to patient motion, target movement or equipment issues to ensure accuracy and safety. The physician also evaluates the patient post-procedure. All other work generally associated with CPT code 77427 (Radiation treatment management, five treatments) is included and should not be separately coded.

Much of the radiation oncologist’s work in establishing the above treatment parameters is performed in conjunction with the qualified medical physicist, who should be present and participate in delivering SBRT.

CPT® CODE	DESCRIPTION	SBRT-SPECIFIC GUIDELINES
77435	Stereotactic body radiation therapy, treatment management, per treatment course, to one or more lesions, including image guidance, entire course not to exceed 5 fractions (Do not report 77435 in conjunction with other treatment management codes 77427- 77432) (The same physician should not report both stereotactic radiosurgery services (32701, 63620, 63621) and radiation treatment management (77435)	Professional charge for treatment management performed by the radiation oncologist. This code can be reported only once for the entire course of treatment and not per fraction. It will apply to all lesions treated during that entire course of treatment. It should not be reported in conjunction with any other treatment management codes (77427-77432).

REFERENCES

General

1. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. *Med Phys*. 2010; 37(8): 4078-4101.
2. Chang R, Timmerman R. Stereotactic Body Radiation Therapy: A Comprehensive Review. *Am J Clin Oncol*. 2007; 30(6): 637-644.
3. Halperin EC, Perez, CA, Brady LW. *Principles and Practice of Radiation Therapy*, 5th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2008.
4. Karnofsky DA, Burchenal JH. (1949). "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." In: MacLeod CM (Ed), *Evaluation of Chemotherapeutic Agents*. Columbia Univ Press. Page 196.
5. Kavanagh BD and Timmerman RD (Eds.) *Stereotactic Body Radiation Therapy*, Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
6. Lo S, Fakiris A, Chang E, et al. *Stereotactic body radiation therapy: a novel treatment modality*. *Nat Rev Clin Oncol*. 2010; 7(1): 44-54.
7. Martin A, Gaya A, Stereotactic Body Radiotherapy: A Review. *Clin Oncol (R Coll Radiol)*. 2010; 22(3): 157-172.
8. Oken MM, Creech RH, Tormey DC, et al. Toxicity And Response Criteria of The Eastern Cooperative Oncology Group. *Am J Clin Oncol*. 1982; 5(6):649-655.
9. Potters L, Kavanagh B, Galvin JM, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2010; 76(2): 326-332.
10. Solberg TD, Balter JM, Benedict SH, et al. Quality and safety considerations in stereotactic radiosurgery and stereotactic body radiation therapy: Executive summary. *Pract Radiat Oncol*. 2012; 2(1): 2-9.
11. Stereotactic Radiosurgery (SRS) Model Coverage Policy. American Society for Radiation Oncology Web site. https://www.astro.org/uploadedFiles/Main_Site/Practice_Management/Reimbursement/SRSMJuly2011.pdf Published July 25, 2011. Accessed April 9, 2014
12. Timmerman RD, Kavanagh BD, Cho LC, et al. Stereotactic Body Radiation Therapy in Multiple Organ Sites. *J Clin Oncol*. 2007; 25(8): 947-952.
16. Degen JW, Gagnon GJ, Voyadzis JM, et al. Cyberknife stereotactic radiosurgical treatment of spinal tumors for pain control and quality of life. *J Neurosurg Spine*. 2005; 2(5): 540-549.
17. Gagnon GJ, Nasr NM, Liao JJ, et al. Treatment of spinal tumors using CyberKnife fractionated stereotactic radiosurgery: pain and quality of life assessment after treatment in 200 patients. *Neurosurgery*. 2009; 64(2): 297-306.
18. Gerstzen PC, Ozhasoglu C, Burton SA, et al. CyberKnife frameless stereotactic radiosurgery for spinal lesions: clinical experience in 125 cases. *Neurosurgery*. 2004; 55(1): 89-98.
19. Haley M, Gerszten P. Stereotactic Radiosurgery in the Management of Cancer Pain. *Curr Pain Headache Rep*. 2009; 13(4): 277-281.
20. Janjan N, Lutz S, Bedwinek J, et al. Therapeutic Guidelines for the Treatment of Bone Metastasis: A Report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. *J Palliat Med*. 2009, 12(5): 417-426.
21. Nelson JW, Yoo DS, Sampson JH, et al. Stereotactic body radiotherapy for lesions of the spine and paraspinal regions. *Int J Radiat Oncol Biol Phys*. 2009; 73(5): 1369-1375.
22. Sahgal A, Ames C, Chou D, et al. Stereotactic Body Radiotherapy Is Effective Salvage Therapy for Patients with Prior Radiation of Spinal Metastases. *Int J Radiat Oncol Biol Phys*. 2008; 71: 652-665.

Oligometastatic Disease

13. Chang EL, Shiu AS, Lii MF, et al. Phase I clinical evaluation of near-simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. *Int J Radiat Oncol Biol Phys*. 2004; 9(5): 1288-1294.
14. Chang EL, Shiu AS, Mendel E, et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. *J Neurosurg Spine*. 2007; 7(2): 151-160.
15. Choi CY, Adler JR, Gibbs IC, et al. Stereotactic Radiosurgery for Treatment of Spinal Metastases Recurring in Close Proximity to Previously Irradiated Spinal Cord. *Int J Radiat Oncol Biol Phys*. 2010; 78(2): 499-506.
23. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. *J Clin Oncol*. 2013; 31(11): 1384-1390.
24. McCammon R, Schefter TE, Gaspar LE, et al. Observation of dose control relationship for lung and liver tumors after stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys*. 2009; 73(1): 112-118.
25. Milano MT, Katz AW, Okunieff P. Patterns of recurrence after curative-intent radiation for oligometastases confined to one organ. *Amer J Clin Oncol*. 2010; 33(2): 157-163.
26. Milano MT, Katz AW, Muhs AG, et al. A prospective pilot study of curative-intent stereotactic radiation therapy in patients with 5 or fewer oligometastatic lesions. *Cancer*. 2008; 112(3): 650-658.
27. Milano MT, Katz AW, Zhang H, et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of a prospective study. *Int J Radiat Oncol Biol Phys*. 2012; 83(3): 878-886.
28. Milano MT, Zhang H, Metcalfe SK, et al. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. *Breast Cancer Res Treat*. 2009; 115(3): 601-608.

Bone Metastasis

Head and Neck

29. Chen HH, Tsai ST, Wang MS, et al. Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2006; 66(5): 1408-1414.
30. Hara W, Loo BW, Goffinet DR, et al. Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2008; 71(2): 393-400.
31. Kawaguchi K, Sato K, Horie A, et al. Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma. *Radiat Oncol.* 2010; 5:51.
32. Kim JH, Kim MS, Yoo SY, et al. Stereotactic body radiotherapy for refractory cervical lymph node recurrence of nonanaplastic thyroid cancer. *Otolaryngol Head Neck Surg.* 2010; 142(3): 338-43.
33. Ozigit G, Cengiz M, Yazici G, et al. A retrospective comparison of robotic stereotactic body radiotherapy and three-dimensional conformal radiotherapy for the reirradiation of locally recurrent nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2011; 81(4):e263-268.
34. Rwigema J, Heron D, Ferris R, et al. Fractionated stereotactic body radiation therapy in the treatment of previously-irradiated recurrent head and neck carcinoma. Updated report of the University of Pittsburgh experience. *Am J Clin Oncol.* 2010; 33(3): 286-293.
35. Unger KR, Lominska CE, Deeken JF, et al. Fractionated Stereotactic Radiosurgery for Reirradiation of Head-and-Neck Cancer. *Int J Radiat Oncol Biol Phys.* 2010; 77(5): 1411-1419.
36. Vargo JA, Wegner RE, Heron DE, et al. Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. *Head Neck.* 2012; 34(8): 1153-61.
37. Wu SX, Chua DT, Deng ML, et al. Outcome of fractionated stereotactic radiotherapy for 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys.* 2007; 69(3): 761-769.

Kidney and Adrenal Gland – Primary and Metastatic Tumors

38. Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience. *Int J Radiat Oncol Biol Phys.* 2012; 82(2): 919-923.
39. Chawla S, Chen Y, Katz A, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. *Int J Radiat Oncol Biol Phys.* 2009; 75(1): 71-75.
40. Holy R, Piroth M, Pinkawa M, et al. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. *Strahlenther Onkol.* 2011; 187(4): 245-251.
41. Siva S, Pham D, Gill S, et al. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. *BJU Int.* 2012; 110(11 Pt B): E737-743.
42. Svedman C, Karlsson K, Rutkowska E, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. *Acta Oncol.* 2008; 47(8): 1578-1583.

Liver – Primary and Metastatic Tumors

43. Andolino DL, Johnson CS, Maluccio M, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2011; 81:e447-453.
44. Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and phase II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. *J Clin Oncol.* 2013; 31(13): 1631-1639.
45. Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: A pooled analysis. *Cancer.* 2011; 117(17): 4060-4069.
46. Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. *BMC Cancer.* 2008; 8: 351.
47. Ibarra RA, Rojas D, Snyder L, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. *Acta Oncol.* 2012; 51(5): 575-583.
48. Katz AW, Carey-Sampson M, Muhs AG, et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. *Int J Radiat Oncol Biol Phys.* 2007; 67(3): 793-798.
49. Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. *BMC Cancer.* 2010; 10:475.
50. Lee MT, Kim JJ, Dinniwell R, et al. Phase I study of individualized stereotactic body radiotherapy for liver metastases. *J Clin Oncol.* 2009; 27: 1585-1591.
51. McCammon R, Scheffer TE, Gaspar LE, et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys.* 2009; 73(1): 112-118.
52. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. *Acta Oncol.* 2006; 45(7): 831-837.
53. Méndez Romero A, Wunderink W, van Os RM, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. *Int J Radiat Oncol Biol Phys.* 2008; 70(5): 1447-1452.
54. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. *Cancer.* 2012; 118(12): 3191-3198.
55. Rusthoven KE, Kavanagh BD, Cardenas H, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. *J Clin Oncol.* 2009; 27(10): 1572-1578.
56. Tao C, Yang LX. Improved radiotherapy for primary and secondary liver cancer: Stereotactic body radiation therapy. *Anticancer Research.* 2012; 32(2): 649-655.
57. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *J Clin Oncol.* 2008; 26(4):657-664.

Lung – Primary and Metastatic Tumors

58. Andratschke N, Zimmermann F, Boehm E, et al. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. *Radiother Oncol.* 2011; 101(2): 245-249.
59. Barriger RB, Forquer JA, Brabham JG, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys.* 2012; 82(1): 457-462.
60. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. *J Clin Oncol* 2009; 27(20): 3290-3296.
61. Baumann P, Nyman J, Hoyer M, et al. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. *Radiother Oncol.* 2008; 88(3): 359-367.
62. Bradley JD, El Naqa I, Drzymala RE, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: the pattern of failure is distant. *Int J Radiat Oncol Biol Phys.* 2010; 77(4):1146-1150.
63. Chang JY, Balter PA, Dong L, et al. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2008; 72(4): 967-971.
64. Chen Y, Guo W, Lu Y, et al. . Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. *Radiother Oncol.* 2008; 88(3): 351-358.
65. Fakiris, AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. *Int J Radiat Oncol Biol Phys.* 2009; 75(3): 677-682.
66. Guckenberger M, Wulf J, Mueller G, et al. Response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4d dose calculation. *Int J Radiat Oncol Biol Phys.* 2009; 73(2): 442-448.
67. Henderson M, McGarry R, Yiannoutsos C, et al. Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2008; 72(2): 404-409.
68. Joyner M, Salter BJ, Papanikolaou N, et al. Stereotactic body radiation therapy for centrally located lung lesions. *Acta Oncol.* 2006; 45(7): 802-807.
69. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. *Radiother Oncol.* 2007; 85(3): 429-434.
70. Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radiotherapy for non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2011; 79(4): 1104-1111.
71. McCammon R, Scheffter TE, Gaspar LE, et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. *Int J Radiat Oncol Biol Phys.* 2009; 73(1): 112-118.
72. Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. *Int J Radiat Oncol Biol Phys.* 2008; 72(2): 398-403.
73. Okunieff P, Petersen AL, Philip A, et al. Stereotactic body radiation therapy (SBRT) for lung metastases. *Acta Oncol.* 2006; 45(7): 808-817.
74. Olsen JR, Robinson CG, El Naqa I, et al. Dose-response for stereotactic body radiotherapy in early-stage non-small cell lung cancer. *Int J Radiat Oncol Biol Phys.* 2011; 81(4): e299-303.
75. Onishi H, Shirato H, Nagata Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small cell lung cancer: can SBRT be comparable to surgery? *Int J Radiat Oncol Biol Phys.* 2011; 81(5): 1352-1358.
76. Pennathur A, Luketick J, Heron D, et al. Stereotactic radiosurgery for the treatment of lung neoplasm: experience in 100 consecutive patients. *Ann Thorac Surg.* 2009; 88: 1594-1600.
77. Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. *J Clin Oncol.* 2009; 27(10): 1579-1584.
78. Salazar OM, Sandhu TS, Lattin PB, et al. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. *Int J Radiat Oncol Biol Phys.* 2008; 72(3): 707-715.
79. Scorsetti M, Navarria P, Facoetti A, et al. Effectiveness of stereotactic body radiotherapy in the treatment of inoperable early-stage lung cancer. *Anticancer Res.* 2007; 27(5B): 3615-3619.
80. Senan S, Lagerwaard F. Stereotactic radiotherapy for stage I lung cancer: Current results and new developments. *Cancer Radiother.* 2010; 14(20): 115-118.
81. Siva S, ManManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. *J Thorac Oncol.* 2010; 5(7): 1091-1099.
82. Stephans KL, Djemil T, Reddy CA, et al. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. *J Thorac Oncol.* 2009; 4(8): 976-982.
83. Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. *Radiother Oncol.* 2011; 101(2): 255-259.
84. Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm. *Int J Radiat Oncol Biol Phys.* 2009; 73(2): 442-448.
85. Taremi M, Hope A, Dahele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients. *Int J Radiat Oncol Biol Phys.* 2012; 82(2):967-973
86. Versteegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with contemporaneous cohort with pathologically proven disease. *Radiother Oncol.* 2011; 101(2) 250-254.
87. Zimmermann F, Wulf J, Lax I, et al. Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer. *Front Radiat Ther Oncol.* 2010; 42: 94-114.

Pancreas

88. Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. *Cancer*. 2009; 115(3): 665-672.
89. Didolkar MS, Coleman CW, Brenner MJ, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma: results of first 85 patients. *J Gastrointest Surg*. 2010; 14:1547-1559.
90. Goyal K, Einstein D, Ibarra RA, et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. *J Syng Res*. 2012; 174(2): 319-325.
91. Mahadevan A, Jain S, Goldstein M, et al. Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer. *Int J Radiat Oncol Biol Phys*. 2010; 78(3): 735-742.
92. Rwigema J, Parihk S, Heron D, et al. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. *Am J Clin Oncol*. 2011; 34(1): 63-69.
93. Seo Y, Kim MS, Yoo S, et al. Stereotactic body radiation therapy boost in locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2009; 75(5): 1556-1461.
94. Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2008; 72: 678-686.

Pelvic, Non-prostate

95. Choi C, Cho C, Yoo S, et al. Image-guided Stereotactic Body Radiation Therapy in Patients with Isolated Para-aortic Lymph Node Metastases from Uterine Cervical and Corpus Cancer. *Int J Radiat Oncol Biol Phys*. 2009; 74(1): 147-153.
96. Kim MS, Choi C, Yoo S, et al. Stereotactic body radiation therapy in patients with pelvic recurrence from rectal carcinoma. *Jpn J Clin Oncol*. 2008; 38(10): 695-700.

Prostate

97. Buyyounouski MK, Price RA, Harris EER, et al. Stereotactic body radiotherapy for primary management of early-stage, low-to intermediate-risk prostate cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. *Int J Radiat Oncol Biol Phys*. 2010; 76(5): 1297-1304.
98. Freeman DF, King CR. Stereotactic body radiation for low-risk prostate cancer: five year outcomes. *Radiat Oncol*. 2011; 6:3.
99. Ishiyama H, Teh BS, Lo SS, et al. Stereotactic body radiation therapy for prostate cancer. *Future Oncol*. 2011; 7(9): 1077-1086.
100. Katz AJ, Santoro M, Diblasio F, et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. *Radiat Oncol*. 2013; 8(1):118.
101. King CR, Brooks JD, Gill H, et al. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. *Int J Radiat Oncol Biol Phys*. 2012; 82(2): 877-882.
102. King CR, Brooks JD, Gill H, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. *Int J Radiat Oncol Biol Phys*. 2009; 73(4): 1043-1048.
103. King CR, Collins S, Fuller D, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. *Int J Radiat Oncol Biol Phys*. 2013; 87(5): 939-945.
104. Madsen BL, Hsi RA, Pham HT, et al. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. *Int J Radiat Oncol Biol Phys*. 2007; 67(4): 1099-1105.
105. Parthan A, Pruttivarasin N, Davies D, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. *Front Oncol*. 2012; 2: 81.
106. Townsend NC, Huth BJ, Ding W, et al. Acute toxicity after Cyberknife-delivered hypofractionated radiotherapy for treatment of prostate cancer. *Amer J Clin Oncol*. 2011; 34(1): 6-10.